Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07144527 · ClinicalTrials.gov registry record · NA
Nicotinamide Mononucleotide Supplementation for Exercise Tolerance Improvement in Healthy Older Adults
A NA study of Aging and Frailty, sponsored by Scott Silveira.
- Recruiting
- Registry status
- NA
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT07144527 is a NA study of Aging and Frailty that is actively recruiting participants, run by Scott Silveira. The registered enrollment target is 40 participants, below the 2,195-participant average among 262 other Aging trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07144527, a NA study of Aging and Frailty, is actively recruiting participants, sponsored by Scott Silveira.
- RECRUITING
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a randomized, double-blind, placebo-controlled, two-arm crossover clinical trial evaluating the effects of a patented age-reversal therapy, EGA®, compared to conventional nicotinamide mononucleotide (NMN) supplementation. The study will assess safety and efficacy in improving exercise tolerance and modulating biomarkers of aging in healthy older adults. The primary outcome is cycle ergometry constant work rate (CWR) exercise tolerance, measured as time to fatigue. Secondary outcomes include changes in peak oxygen consumption (VO₂peak), critical power, anaerobic work capacity, lactate threshold, and NAD⁺ metabolite levels. EGA® is composed of three metabolomic compounds that are endogenous to humans. The formulation has been used in prior exploratory studies and real-world applications, which have helped inform the design of this current trial.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT NMN, betaine, low-dose hydrogen peroxide (EGA)
- DIETARY_SUPPLEMENT Nicotinamide Mononucleotide (NMN)
Study Locations (1)
California
- Medical Office of Dr. Robert Huizenga MD - Beverly Hills
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2026-02-21 |
| Est. Completion | 2027-01-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07144527
The ClinicalTrials.gov registry entry for NCT07144527 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,195-participant average among 262 other Aging trials with a reported enrollment target (98% lower). The listed sponsor is Scott Silveira, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Aging appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT07144527 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT07144527 about?
NCT07144527 is a clinical study titled "Nicotinamide Mononucleotide Supplementation for Exercise Tolerance Improvement in Healthy Older Adults". This is a randomized, double-blind, placebo-controlled, two-arm crossover clinical trial evaluating the effects of a patented age-reversal therapy, EGA®, compared to conventional nicotinamide mononucleotide (NMN) supplementation. The study will assess safety and efficacy in improving exercise tolera...
What is the current status of trial NCT07144527?
This trial is currently recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2026-02-21. Estimated completion is 2027-01-01.
What conditions does trial NCT07144527 study?
This clinical trial studies the following conditions: Aging, Frailty, Healthy Male and Female Subjects, Exercise Tolerance.
What interventions are being tested in trial NCT07144527?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), NMN, betaine, low-dose hydrogen peroxide (EGA) (DIETARY_SUPPLEMENT), Nicotinamide Mononucleotide (NMN) (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT07144527?
This trial is sponsored by Scott Silveira, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07144527 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Aging
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ketone Ester And Salt (KEAS) in Older Adults
RECRUITING · NA
-
Using Nicotine to Reverse Age-related Auditory Processing Deficits
RECRUITING · NA
-
Heterogeneity of Vascular Adaptations to Exercise With Aging in Women and Men
RECRUITING · NA
-
Modulating Neurocognitive Processes of Learning to Trust and Distrust in Aging
RECRUITING · NA
-
Studying the Effects of Digital Interventions on Cognition, Wellbeing, Stress, and Sleep in Older Adults
RECRUITING · NA
-
The GLUCID Study: Effect of Alcohol Reduction and Probiotic Interventions on Cognition and Brain Glucose Metabolism in Normal Aging Adults Who Are High-Risk Alcohol Drinkers
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.